Recommendations for the management of malignant gliomas in the elderly

Expert Review of Anticancer Therapy

Volumn 3, Issue 5, 2003, Pages 643-654

  Basso, Umberto ^a   Monfardini, Silvio ^a   Brandes, Alba ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chemotherapy; Elderly; Malignant glioma; Radiotherapy

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CORTICOSTEROID; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; LOMUSTINE; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; BRAIN HEMORRHAGE; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CATARACT; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CONVULSION; DEPRESSION; DRUG BIOAVAILABILITY; FRACTURE; GASTRITIS; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LEUKOPENIA; LIVER TOXICITY; MUSCLE ATROPHY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0242350975     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.5.643     Document Type: Review

References (74)

1. Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit. Rev. Oncol. Hematol. 39, 219-226 (2001).
2. Greig NH, Ries LG, Yanicik R, Rapoport SI. Increasing annual incidence of primary malignant brain tumors in the elderly. J. Natl Cancer Inst. 82, 1621-1624 (1990).
3. Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 76, 1634-1642 (1995).
4. Fleury A, Menegoz F, Grosclaude P et al. Descriptive epidemiology of cerebral gliomas in France. Cancer 79, 1195-1202 (1997).
5. Shugg D, Allen BJ, Blizzard L et al. Brain cancer incidence, mortality and case survival: observations from two Australian cancer registries. Int. J. Cancer 59, 765-770 (1994).
6. Larsen NS. Brain tumor incidence rising: researchers ask why. J. Natl. Cancer Inst. 85, 1024-1025 (1993).
7. Boyle P, Maisonneuve P, Saracci R et al. Is the increased incidence of primary malignant brain tumors in the elderly real? J. Natl Cancer Inst. 82, 1594-1599 (1990).
8. Polednak AP. Increased mortality from brain tumors: a combined outcome of diagnostic technology and change of attitude toward the elderly. Am. J. Epidemiol. 140, 1238-1243 (1994).
9. Brandes AA, Fiorentino MV. Treatment of high-grade gliomas in the elderly. A review. Oncology 55, 1-6 (1998).
10. Riggs JE. Rising primary malignant brain tumor mortality in the elderly: a manifestation of differential survival. Arch. Neurol. 52, 571-575 (1995).
11. Ahsan H, Neugut AI, Bruce JN. Trends in incidence of primary malignant brain tumors in USA, 1981-1990. Int. J. Epidemiol. 24, 1078-1085 (1995).
12. Radhakrishnan K, Mokri B, Parisi JE et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann. Neurol. 37, 67-73 (1995).
13. Burger PC. Malignant astrocytic neoplasms: classification, pathologic anatomy and response to treatment. Semin. Oncol. 13, 16-26 (1986).
14. World Health Organization. Pathology and genetics: tumors of the nervous system. Kleihues P, Cavanee WK (Eds), IARC press, Lyon, France (2000).
15. Burger PC, Green SB. Patient age, histologic features and length of survival in patients with glioblastoma multiforme. Cancer 59, 1617-1625 (1987).
16. Malaguarnera L, Ferlito L, Di Mauro S. Immunosenescence and cancer: a review. Arch. Gerontol. Geriatr. 32, 77-93 (2001).
17. Kunwar S, Mohapatra G, Bollen A et al. Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res. 61, 7683-7688 (2001).
18. Burton EC, Lamborn KR, Feuerstein BG et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res. 62, 6205-6210 (2002).
19. Barker FG, Simmons ML, Chang SM et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 51, 410-418 (2001).
20. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahadi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int. J. Radiat. Oncol. Biol. Phys. 34, 809-815 (1996).
21. Waha A, Baumann A, Wolf HK et al. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-α pathway in human astrocytic gliomas. Am J. Neurosurg. 85, 634-641 (1996).
22. Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor and survival in glioblastoma patients. Cancer Res. 61, 1121-1128 (2001).
23. Lowry JK, Snyder JJ, Lowry PW. Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch. Neurol. 55, 922-928 (1998).
24. Steinfeld AD, Donahue B, Walker I. Delay in the diagnosis of glioblastoma multiforme: is age a factor? Cancer Invest. 14, 317-319 (1996).
25. Curran WJ, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst. 85, 704-710 (1993).
26. Extermann M. Measuring comorbidity in older cancer patients. Eur. J. Cancer 36, 453-471 (2000).
27. Monfardini S, Balducci L. A comprehensive geriatric assessment (CGA) is necessary for the study and the management of cancer in the elderly. Eur. J. Cancer 35, 1771-1772 (1999).
28. Cascinu S, Del Ferro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am. J. Clin. Oncol. 19, 371-374 (1996).
29. Brandes AA, Scelzi E, Salmistraro G et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur. J. Cancer 33, 1592-1596 (1997).
30. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch. Intern. Med. 160, 2327-2332 (2000).
31. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr. Opin. Pulm. Med. 7, 326-331 (2001).
32. Colleoni M, Mandala M, Peruzzotti G et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356, 1326-1327 (2000).
33. Pietila TA, Stendel R, Hassler WE et al. Brain tumor surgery in geriatric patients: a critical analysis in 44 patients over 80 years. Surg. Neurol. 52, 259-264 (1999).
34. Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 34, 62-67 (1994).
35. Muacevic A, Kreth FW. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J. Neurol. 250, 561-568 (2003).
36. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Co-operative Group. J. Clin. Oncol. 6, 338-343 (1988).
37. Whittle IR, Basu N, Grant R et al. Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br. J. Neurosurg. 16, 343-347 (2002).
38. Kreth FW, Berlis A, Spiropoulou V et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 86, 2117-2123 (1999).
39. DeAngelis LM. Brain tumors. N. Engl. J. Med. 344, 114-123 (2000).
40. Mohan DS, Suh JH, Phan JL et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int. J. Radiat. Oncol. Biol. Phys. 42, 981-987 (1998).
41. Pierga JY, Hoang-Xuan K, Feuvret L et al. Treatment of malignant gliomas in the elderly. J. Neurooncol. 43, 187-193 (1999).
42. Chang EL, Yi W, Allen PK et al. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 56, 519-528 (2003).
43. Ampil F, Fowler M, Kim K. Intracranial astrocytoma in elderly patients. J. Neurooncol. 12, 125-130 (1992).
44. Hoegler DB, Davey P. A prospective study of short course of radiotherapy in elderly patients with malignant glioma. J. Neurooncol. 33, 201-204 (1997).
45. Meckling S, Dold O, Forsyth P et al. Malignant supratentorial glioma in the elderly. Is radiotherapy useful? Neurology 47, 901-905 (1996).
46. Villa S, Vinolas N, Verger E et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int. J. Radiat. Oncol. Biol. Phys. 42, 977-980 (1998).
47. Laperriere N, Zuraw L, Cairncross G et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother. Oncol. 64, 259-273 (2002).
48. Rajan B, Pickuth D, Ashley S et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 28, 405-413 (1994).
49. Barker FG, Chang SM, Larson DA et al. Age and radiation response in glioblastoma multiforme. Neurosurgery 49, 1288-1297 (2001).
50. Brandes AA, Rigon A, Monfardini S. Radiotherapy of the brain in elderly patients. Contra. Eur. J. Cancer 36, 447-451 (2000).
51. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Oncology Therapy Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int. J. Radiat. Oncol. Biol. Phys. 31, 1341-1350 (1995).
52. Walker MD, Alexander E, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a co-operative clinical trial. J. Neurosurg. 49, 333-343 (1978).
53. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of Grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumor Working Party. Br. J. Cancer 64, 769-774 (1991).
54. Gilbert MR, Bozik M, Armstrong TS et al. Aggressive chemotherapy treatment of brain tumors in the elderly: results from Phase II study. Proc. Am. Soc. Clin. Oncol. 15 (1996) (Abstract 271a).
55. Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in the elderly. Cancer 297, 657-662 (2003).
56. Newall J, Ransohoff J, Kaplan B. Glioblastoma in the older patient. How long a course of radiotherapy is necessary? J. Neurooncol. 6, 325-327 (1988).
57. Bauman GS, Gaspar LE, Fisher BJ et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 29, 835-839 (1994).
58. Glioma Meta-Analysis Trial (GM1) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018 (2002).
59. DeAngelis LM, Burger PC, Green SB et al. Malignant gliomas: who benefits from adjuvant chemotherapy? Ann. Neurol. 44, 691-695 (1998).
60. Rosenblum ML, Gerosa M, Dougherty DV et al. Age-related chemosensitivity of stem cells from human malignant brain tumors. Lancet 1(8277), 885-887 (1982).
61. Grant R, Liang BC, Page MA et al. Age influences chemotherapy response in astrocytomas. Neurology 45, 929-933 (1995).
62. Piribauer M, Fazeny-Dorner B, Rossler K et al. Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme. Anticancer Drugs 14, 137-143 (2003).
63. Brandes AA, Pasetto LM, Vastola F et al. Temozolomide in patients with high grade gliomas. Oncology 59, 181-186 (2000).
64. Dinnes J, Cave C, Huang S et al. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer 86, 501-505 (2002).
65. Brandes AA. State of the art in the treatment of malignant gliomas. Semin. Oncol. (2003) (In Press).
66. Chinot O, Barrie M, Fauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 78a).
67. Glantz M, Chamberlain M, Liu Q et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97, 2262-2262 (2003).
68. DeAngelis LM. Radiotherapy of the brain in elderly patients. Eur. J. Cancer 36, 451-452 (2000).
69. Hutchins LF, Unger JM, Crowley JJ et al. Under-representation of patients 65 years of age or older in cancer treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
70. Chang SM, Barker FG, Schmidt MH et al. Clinical trial participation among patients enrolled in the Glioma Outcomes Project. Cancer 94, 2681-2687 (2002).
71. Benson AB III, Pregler JP, Bean JA et al. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J. Clin. Oncol. 9, 2067-2075 (1991).
72. Murray KJ, Nelson DF, Scott C et al. Quality-adjusted survival analysis of malignant glioma in patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 8302. Int. J. Radiat. Oncol. Biol. Phys. 31, 453-459 (1995).
73. Brandes AA, Basso U, Pasetto LM. Changing boundaries in the treatment of high-grade glioma. Expert Rev. Anticancer Ther. 1(3), 89-102 (2001).
74. Basso U, Ermani M, Vastola F et al. Non-cytotoxic therapies for malignant gliomas. J. Neurooncol. 58, 57-69 (2002).